The strong efficacy and safety data in a hard-to-treat population de-risks the nuzefatide program and supports its expansion into pancreatic cancer. Traders should monitor upcoming clinical milestones and potential partnerships for the EphA2 platform.
Price Chart
Executive Summary
Bicycle Therapeutics announced positive Phase 1/2 clinical data for its nuzefatide pevedotin in combination with nivolumab in metastatic urothelial cancer, demonstrating a 40% confirmed overall response rate in EphA2+ tumors, and announced the first patient dosed in its Phase 2 trial for pancreatic ductal adenocarcinoma. The company also presented human imaging data supporting EphA2 as a viable cancer target.
Key Facts
- Phase 1/2 trial of nuzefatide pevedotin + nivolumab in metastatic urothelial cancer showed 40% confirmed ORR in EphA2+ patients and 100% ORR in MMAE-naïve patients
- Nuzefatide demonstrated a favorable safety profile with no Grade ≥3 TRAEs of clinical interest
- First patient dosed in Phase 2 trial for recurrent pancreatic ductal adenocarcinoma at 8mg/m² Q2W dose
- Human imaging data with EphA2-targeting Bicycle Imaging Agent confirmed tumor uptake and metastasis detection in PDAC patients
- Preclinical data showed nuzefatide sensitivity in 10 of 14 PDAC PDX models, with 6 showing high sensitivity
Financial Impact
No direct financial impact disclosed; advancement of clinical pipeline may improve future revenue potential
Risk Factors
- Clinical trial results may not be reproducible in larger studies
- Future regulatory approval is uncertain
- Competitive landscape in urothelial and pancreatic cancers is intense
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-045198 |
| Document: tm2612166d1_ex99-1.htm | 0001104659-26-045198 |
| Document: 0001104659-26-045198-index-headers.html | 0001104659-26-045198 |
| Document: 0001104659-26-045198-index.html | 0001104659-26-045198 |
| Document: 0001104659-26-045198.txt | 0001104659-26-045198 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 3/A | $3.73 | awaiting T+60 | — | $3.65 (−2.14%) |
Jul 30, 2026 12w ago | 8-K | $4.01 $3.55 | ▼ −11.47% | ▼ −13.94% | $3.65 (−8.98%) |
May 21, 2026 22w ago | 8-K | $4.55 $3.99 | ▼ −12.31% | ▼ −15.50% | $3.65 (−19.78%) |
Apr 20, 2026 27w ago | 8-K | $5.29 $4.22 | ▼ −20.23% | ▼ −27.00% | $3.65 (−31.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers